FDA Approves Genentechs Lucentis (Ranibizumab Injection) for Treatment of Diabetic Retinopathy in People with Diabetic Macular Edema

On November 14, 2014, a Genentech medicine received FDA approval for use in a specific type of platinum-resistant ovarian cancer.

On February 6, 2015, the FDA approved a Genentech Medicine for the treatment of diabetic retinopathy in people with diabetic macular edema (DME).

Presentations, Posters, and Papers galore. Check out our ACR 2014 newsroom to learn more about our commitment to rheumatology.

Genentech will present important new ophthalmic data at the 118th Annual Meeting of the American Academy of Ophthalmology (AAO) from October 18-21 in Chicago.

On October 15, 2014, the FDA approved a medicine for the treatment of idiopathic pulmonary fibrosis (IPF).

Read about Genentechs planned acquisition of Seragon.

With the recent acquisition of Seragon, Genentech is excited to add a new class of investigational medicines known as SERDs to our pipeline.

Genentech fully supports efforts to increase transparency around the partnership between the industry and healthcare professionals.

Medicine for people with chronic idiopathic urticaria (CIU), a form of chronic hives.

Read more here:

GENE - Genentech